Lunate Capital Acquires 200,000 Shares of Navan for $3.42 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2026
0mins
Should l Buy NAVN?
Source: Yahoo Finance
- New Investment Position: Lunate Capital acquired 200,000 shares of Navan in Q4 2023 for $3.42 million, representing 1.29% of its reportable assets, indicating a cautiously optimistic outlook on Navan's future growth.
- Stock Price Volatility: Despite a 60% drop in Navan's stock price since its IPO, currently priced at $15.09, the company reported a 29% year-over-year revenue increase in its latest earnings release, suggesting resilience in its fundamentals.
- Market Performance and Customer Feedback: Navan's gross booking volume surged 40% to $2.6 billion, with the CEO noting continued momentum in the enterprise market and new highs in customer satisfaction, reflecting widespread adoption of its AI platform.
- Investor Strategy Consideration: With nearly 90% of Lunate Capital's capital concentrated in three stocks, this small investment in Navan appears more as a cautious probe rather than a strong conviction, prompting investors to monitor execution closely.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAVN
Wall Street analysts forecast NAVN stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.400
Low
13.99
Averages
23.64
High
30.00
Current: 9.400
Low
13.99
Averages
23.64
High
30.00
About NAVN
Navan, Inc. is an end-to-end, artificial intelligence (AI) powered software platform built to simplify global business travel and expense (T&E) experience, helping users, customers, and suppliers. Its solutions include Navan Cloud-The Infrastructure of its Travel Experience, Navan Native Apps and Enterprise Integrations, and Navan Cognition-its New Paradigm in AI-Powered Travel Management. Navan Cloud-The Infrastructure of its Travel Experience is its proprietary technology and partner infrastructure from the ground up to provide a global, real-time inventory that maximizes choice for its users. Its platform is global, with a broad inventory including smaller suppliers, and its human and virtual agents have access to all the bookings on its platform, globally. Navan Cognition-its New Paradigm in AI-Powered Travel Management is its third-generation proprietary AI framework that combines the precision and predictive machine learning with the reasoning capabilities of large language mode.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Navan Securities Class Action Lawsuit Reminder for Investors
- Filing Deadline: ClaimsFiler reminds Navan shareholders that they must file lead plaintiff applications by April 24, 2026, to participate in the securities class action lawsuit related to the company's October 2025 IPO.
- Legal Allegations: Navan and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, including a 39% increase in sales and marketing expenses to nearly $95 million for the quarter ending October 31, 2025, compared to $68.5 million in the previous quarter.
- Stock Price Impact: Following the revelation of true details, Navan's stock price fell sharply, indicating investor concerns over the company's financial transparency and potentially leading to significant investor losses.
- Legal Assistance: Investors can access legal support through ClaimsFiler's website to learn how to file claims, with Kahn Swick & Foti, LLC offering free legal consultations to help investors evaluate their legal options.
See More
Navan, Inc. Faces Class Action Lawsuit Post-IPO
- Class Action Initiation: Navan, Inc. is facing a class action lawsuit due to its October 31, 2025 IPO, with plaintiffs alleging violations of the Securities Act of 1933, and they must apply to be lead plaintiff by April 24, 2026.
- Poor IPO Performance: Navan issued nearly 37 million shares at $25 each during its IPO, but the lawsuit claims the offering documents were materially false or misleading, resulting in the stock price dropping to $9.20 per share, a nearly 63% decline by the time the lawsuit commenced.
- Surge in Sales Expenses: The lawsuit alleges that Navan increased its sales and marketing expenses by 39% shortly after the IPO, from $68.5 million to nearly $95 million, which led to a nearly 12% drop in stock price following the December 2025 earnings report.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant capabilities in securities class action cases.
See More
Class Action Lawsuit Filed Against Navan, Inc. for IPO Misrepresentation
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors of Navan, Inc. regarding a class action lawsuit due to the company's failure to disclose critical information during its October 2025 IPO, aiming to recover losses for affected investors.
- Financial Misrepresentation Allegations: The complaint alleges that Navan's sales and marketing expenses surged to nearly $95 million in Q4 2025, a 39% increase from $68.5 million in Q3 2025, which was not disclosed in the offering documents, leading to investor losses.
- Stock Price Impact: Following the revelation of true financial details, Navan's stock price plummeted, indicating a severe loss of market confidence in the company's financial health, which could hinder future fundraising efforts.
- Investor Action Recommendation: Affected investors have until April 24, 2026, to apply to be lead plaintiffs in the lawsuit, highlighting significant deficiencies in the company's transparency and accountability practices.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
Class Action Lawsuit Announced for Navan, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Navan, Inc. (NASDAQ: NAVN) common stock related to its October 2025 IPO, alleging that the Offering Documents contained false and misleading information that may have led to investor losses.
- Compensation Structure: Investors who purchased Navan common stock may be entitled to compensation through a contingency fee arrangement without any upfront costs, indicating a protective measure for investor rights that could impact Navan's market reputation.
- Lawsuit Details: The lawsuit claims that Navan failed to disclose an increase in its “sales and marketing” expenses at the time of the IPO, resulting in investor damages when the true information became public, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Navan Faces Securities Class Action Lawsuit
- Deteriorating Financial Performance: Navan's Q3 2026 financial results revealed a shocking 39% sequential increase in sales and marketing expenses, leading to a fourfold year-over-year increase in net losses, which severely impacted investor confidence and caused the stock price to drop nearly 12% to $12.90 on December 16, 2025, approximately 48% below the IPO price.
- IPO Document Controversy: The lawsuit alleges that Navan failed to disclose adverse trends in sales and marketing expenses in its IPO documents, despite previously claiming a 33% year-over-year revenue growth from 2024 to 2025, raising significant concerns about the transparency of its disclosures.
- Executive Departure Impact: The unexpected departure of CFO Amy Butte on January 9, 2026, heightened market concerns regarding the company's governance and financial health, resulting in the stock price plummeting to $9.16 by the time the lawsuit was filed, reflecting a 63% decline from the IPO price.
- Legal Investigation Initiated: Hagens Berman has launched an investigation into Navan and its executives to assess whether there was a lack of legal transparency during the IPO, urging investors who suffered losses to contact the firm to protect their rights.
See More
Navan Securities Class Action Lawsuit Reminder for Investors
- Filing Deadline: ClaimsFiler reminds Navan shareholders that they must file lead plaintiff applications by April 24, 2026, to participate in the securities class action lawsuit related to the company's October 2025 IPO.
- Legal Allegations: Navan and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, including a 39% increase in sales and marketing expenses to nearly $95 million for the quarter ending October 31, 2025, compared to $68.5 million in the previous quarter.
- Stock Price Impact: Following the revelation of true details, Navan's stock price fell sharply, indicating investor concerns over the company's financial transparency and potentially leading to significant investor losses.
- Legal Assistance: Investors can access legal support through ClaimsFiler's website to learn how to file claims, with Kahn Swick & Foti, LLC offering free legal consultations to help investors evaluate their legal options.
See More
Navan, Inc. Faces Class Action Lawsuit Post-IPO
- Class Action Initiation: Navan, Inc. is facing a class action lawsuit due to its October 31, 2025 IPO, with plaintiffs alleging violations of the Securities Act of 1933, and they must apply to be lead plaintiff by April 24, 2026.
- Poor IPO Performance: Navan issued nearly 37 million shares at $25 each during its IPO, but the lawsuit claims the offering documents were materially false or misleading, resulting in the stock price dropping to $9.20 per share, a nearly 63% decline by the time the lawsuit commenced.
- Surge in Sales Expenses: The lawsuit alleges that Navan increased its sales and marketing expenses by 39% shortly after the IPO, from $68.5 million to nearly $95 million, which led to a nearly 12% drop in stock price following the December 2025 earnings report.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant capabilities in securities class action cases.
See More
Class Action Lawsuit Filed Against Navan, Inc. for IPO Misrepresentation
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors of Navan, Inc. regarding a class action lawsuit due to the company's failure to disclose critical information during its October 2025 IPO, aiming to recover losses for affected investors.
- Financial Misrepresentation Allegations: The complaint alleges that Navan's sales and marketing expenses surged to nearly $95 million in Q4 2025, a 39% increase from $68.5 million in Q3 2025, which was not disclosed in the offering documents, leading to investor losses.
- Stock Price Impact: Following the revelation of true financial details, Navan's stock price plummeted, indicating a severe loss of market confidence in the company's financial health, which could hinder future fundraising efforts.
- Investor Action Recommendation: Affected investors have until April 24, 2026, to apply to be lead plaintiffs in the lawsuit, highlighting significant deficiencies in the company's transparency and accountability practices.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
Class Action Lawsuit Announced for Navan, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Navan, Inc. (NASDAQ: NAVN) common stock related to its October 2025 IPO, alleging that the Offering Documents contained false and misleading information that may have led to investor losses.
- Compensation Structure: Investors who purchased Navan common stock may be entitled to compensation through a contingency fee arrangement without any upfront costs, indicating a protective measure for investor rights that could impact Navan's market reputation.
- Lawsuit Details: The lawsuit claims that Navan failed to disclose an increase in its “sales and marketing” expenses at the time of the IPO, resulting in investor damages when the true information became public, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Navan Faces Securities Class Action Lawsuit
- Deteriorating Financial Performance: Navan's Q3 2026 financial results revealed a shocking 39% sequential increase in sales and marketing expenses, leading to a fourfold year-over-year increase in net losses, which severely impacted investor confidence and caused the stock price to drop nearly 12% to $12.90 on December 16, 2025, approximately 48% below the IPO price.
- IPO Document Controversy: The lawsuit alleges that Navan failed to disclose adverse trends in sales and marketing expenses in its IPO documents, despite previously claiming a 33% year-over-year revenue growth from 2024 to 2025, raising significant concerns about the transparency of its disclosures.
- Executive Departure Impact: The unexpected departure of CFO Amy Butte on January 9, 2026, heightened market concerns regarding the company's governance and financial health, resulting in the stock price plummeting to $9.16 by the time the lawsuit was filed, reflecting a 63% decline from the IPO price.
- Legal Investigation Initiated: Hagens Berman has launched an investigation into Navan and its executives to assess whether there was a lack of legal transparency during the IPO, urging investors who suffered losses to contact the firm to protect their rights.
See More
